SCINTIX® autonomous radiotherapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our platform uses to manage motion and autonomously treat solid tumors of any stage of disease.
Our SCINTIX technology autonomously delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.
Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.
Treating cancer isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.
By combining PET-CT and radiotherapy, we're able to find and treat cancer using emissions created by tumors themselves.
Discover SCINTIX therapy.
See how SCINTIX therapy can play a role
in your cancer program.
Company also announces participation in annual J.P. Morgan Healthcare Conference HAYWARD, Calif., Jan. 8, 2026 – RefleXion Medical, an external-beam theranostic oncology company, today announced the U.S. Food and Drug Administration has cleared its next generation, autonomously-guided oncology platform, the RefleXion® X2 with SCINTIX® therapy, for the treatment of primary and metastatic lung and bone […]
When Susanne Kluh learned about SCINTIX therapy from RefleXion, she was uniquely qualified to appreciate the opportunity before her. THE ONCOLOGIST’S ASSESSMENT of her cancer was dire, but Susanne Kluh wasn’t about to let him have the final word. “He said, ‘We can’t treat it. Maybe we could do chemotherapy, but wouldn’t you rather have […]
Let us tell you more.
Contact UsStay up to date.
Sign Up